Your browser doesn't support javascript.
loading
Biomarker Testing for People With Advanced Lung Cancer in England.
Adizie, Jana B; Tweedie, Judith; Khakwani, Aamir; Peach, Emily; Hubbard, Richard; Wood, Natasha; Gosney, John R; Harden, Susan V; Beckett, Paul; Popat, Sanjay; Navani, Neal.
Afiliação
  • Adizie JB; Department of Respiratory Medicine, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom.
  • Tweedie J; Department of Cardiovascular Medicine, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
  • Khakwani A; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Nottingham, United Kingdom.
  • Peach E; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Nottingham, United Kingdom.
  • Hubbard R; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Nottingham, United Kingdom.
  • Wood N; Public Health England, National Cancer Registration and Analysis Service, London, United Kingdom.
  • Gosney JR; Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Harden SV; Cancer Research Program, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.
  • Beckett P; Department of Respiratory Medicine, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom.
  • Popat S; Department of Medicine, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Navani N; Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom.
JTO Clin Res Rep ; 2(6): 100176, 2021 Jun.
Article em En | MEDLINE | ID: mdl-34590024
INTRODUCTION: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. METHODS: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. RESULTS: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. CONCLUSIONS: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article